Gut Liver.  2016 Mar;10(2):255-261. 10.5009/gnl15165.

Efficacy of Adalimumab in Korean Patients with Crohn's Disease

• Sohn IW
• Kim ST
• Kim B
• Lee HJ
• Park SJ
• Hong SP
• Kim TI
• Kim WH
• Cheon JH

• KMID: 2363971
• DOI: http://doi.org/10.5009/gnl15165

Abstract

BACKGROUND/AIMS
Adalimumab is effective for both remission induction and the maintenance of Crohn's disease (CD) in Western countries. We evaluated the efficacy of adalim-umab in the conventional step-up treatment approach for CD in Korea.
METHODS
We retrospectively reviewed 62 patients with CD who were treated with adalimumab. Their Crohn's disease activity index (CDAI) was measured at weeks 4, 8, and 52. Clinical remission was defined as a CDAI score <150. Induction and maintenance outcomes were analyzed.
RESULTS
Forty-one patients (66.1%) achieved a reduction of 70 CDAI points at week 8. Among them, 28 (45.2%) achieved clinical remission at week 8, 20 (32.3%) maintained remission at week 52. The absence of prior anti-tumor necrosis factor (TNF) therapy and Montreal classification L1 at baseline predicted clinical remission at week 8 in the multivariate logistic regression analysis. In the Cox proportional hazards model, the hazard ratio for the secondary loss of response during maintenance therapy after clinical remission induction was significantly higher in patients who showed initial mild CDAI severity or Montreal classification A3.
CONCLUSIONS
In our study, anti-TNF therapy-naive and Montreal classification L1 were associated with adalimumab efficacy as induction therapy in CD. Further studies are warranted to determine the prognostic factors for the long-term response after adalimumab therapy.

Keyword

Crohn disease; Adalimumab; Remission induction; Treatment outcome

MeSH Terms

Adalimumab/*therapeutic use
Adolescent
Adult
Anti-Inflammatory Agents/*therapeutic use
Crohn Disease/*drug therapy
Female
Humans
Male
Middle Aged
Proportional Hazards Models
Remission Induction/methods
Republic of Korea
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Young Adult
Adalimumab
Anti-Inflammatory Agents